The "Medicines for the People Act" proposes to amend the Public Health Service Act by establishing a National Institute for Biomedical Research and Development . The Institute's core purpose is to engage in the full-cycle development of drugs, devices, and biological products. This initiative aims to promote long-term access to medicines, foster innovation, and ensure that public health needs are prioritized, ultimately making these essential products available to the public at equitable and accessible prices. The Institute would carry out a comprehensive research and development program, including direct R&D at federal laboratories, contracting with public or private entities, and acquiring existing technologies. It would also be responsible for conducting clinical trials to generate safety and effectiveness data for FDA approval and performing health technology assessments to evaluate the value of products. These assessments would consider clinical effectiveness, safety, costs, ethical implications, and patient impact, while the Institute would also monitor existing research to identify promising inventions and have the right of first refusal to acquire rights to NIH-funded inventions. A key provision emphasizes transparency , requiring the Institute to share preclinical and clinical trial data, cost data, and information on its activities and licensing agreements with the public. Entities receiving Institute funding would be mandated to share scientific data promptly and submit peer-reviewed manuscripts to public databases. Crucially, the bill stipulates that the Federal Government will own the rights to patents and trade secrets resulting from Institute-funded or conducted research, departing from standard patent law, and these patents would be managed in the public interest, with a preference for licensing to the Medicines Patent Pool and ensuring public interest access in terms of price and supply. The Institute would prioritize public manufacturing of federally patented drugs, devices, or biological products, selling them at cost when practicable. If public manufacturing is not feasible, the Director may license patents to private entities, giving preference to nonprofit organizations and reinvesting royalties into further research. A Governing Board , composed of civil society representatives, patient advocates, and public health officials, would be established to set high-level policy, conduct long-term planning, and provide overall direction for the Institute, with specific limitations on membership to prevent conflicts of interest from the for-profit pharmaceutical sector. The Secretary would supervise both the Director and the Governing Board, retaining authority to approve or modify Board decisions. The bill mandates annual evaluations of the Institute's activities, including metrics on product development, licensing, and estimated savings to public healthcare programs, with reports submitted to Congress and made publicly available. To fund these extensive operations, the bill authorizes an appropriation of $90,000,000,000 for fiscal year 2027 , to remain available until expended.